Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants-Reference-Cited by-同舟云学术

Pre-transplant reduction of isohaemagglutinin titres by donor group plasma infusion does not reduce the incidence of pure red cell aplasia in major ABO-mismatched transplants

Published:2005-05-23 Issue:3 Volume:36 Page:233-235
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Damodar S,George B,Mammen J,Mathews V,Srivastava A,Chandy M

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705031.pdf

Reference24 articles.

1. Petz LD . Immunohematologic problems associated with bone marrow transplantation. Transfus Med Rev 1987; 1: 85–100.

2. Mielcarek M, Leisenring W, Tork-Storb B, Storb R . Graft versus host disease and donor directed haemagglutinin titres after ABO-mismatched related and unrelated marrow allografts: evidence for a graft versus plasma cell effect. Blood 2000; 96: 1150–1156.

3. Eastlund T . The histo-blood group ABO system and tissue transplantation. Transfusion 1998; 38: 975–988.

4. Stussi G, Seebach L, Muntwyler J et al. Graft versus host disease and survival after ABO incompatible allogeneic bone marrow transplantation: a single center experience. Br J Haematol 2001; 113: 251–253.

5. Bensinger WI, Buckner CD, Thomas ED et al. ABO incompatible marrow transplants. Transplantation 1982; 33: 427–429.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review;Frontiers in Oncology;2024-07-02

2. Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches;Expert Opinion on Investigational Drugs;2022-09-02

3. Pre-transplant donor-type red cell transfusion is a safe and effective strategy to reduce isohemagglutinin titers and prevent donor marrow infusion reactions in major ABO-mismatched transplants;Annals of Hematology;2021-06-19

4. Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study;British Journal of Haematology;2021-04-12

5. Blood Product Support in HSCT;Contemporary Bone Marrow Transplantation;2021